BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cystic Fibrosis Foundation Issues Statement on The New England Journal of Medicine Study Showing Evidence of Success in Treating Underlying Cause of Cystic Fibrosis


11/3/2011 11:03:39 AM

BETHESDA, Md., Nov. 2, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation issued the following statement in response to study results published today by TheNew England Journal of Medicine offering first evidence that the underlying cause of cystic fibrosis in select patient groups can be treated through a new drug, Kalydeco (Ivacaftor, VX-770).

"The New England Journal of Medicine study marks an important and exciting milestone for the cystic fibrosis community, and it confirms that we are one step closer to finding a cure for the disease," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. "Nearly every CF drug available today was made possible with Foundation support, and Vertex Pharmaceuticals' Kalydeco is the latest example of our venture philanthropymodel at work. We are excited about the opportunity this treatment presents if approved by the FDA for those CF patients who can benefit from this new drug."

Kalydeco, developed by Vertex Pharmaceuticals with CF Foundation support and research input, is the first CF drug to correct a specific genetic defect mutation G551D in select CF patient groups. The drug is currently under review for approval by the U.S. Food and Drug Administration. For more information, click here http://investors.vrtx.com/releasedetail.cfm?ReleaseID=616097.

To view TheNew England Journal of Medicine study and editorial, click here http://www.nejm.org/doi/full/10.1056/NEJMoa1105185?query=featured_home.

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.

SOURCE Cystic Fibrosis Foundation


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->